Exhibit (a)(5)(B)

BREAKING: Endo has reached an agreement to acquire BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company. We are excited by the transaction, which we anticipate will close by the end of the year. Read more about today’s announcement in our press release: https://lnkd.in/eRqg3th “Acquiring BioSpecifics is consistent with our strategic priority to expand and enhance our portfolio through additional investment in the significant long-term growth potential of both XIAFLEX’!C and Qwo”’- two of our most durable and differentiated products. This will also immediately enhance Endo’s adjusted EBITDA and create significant value for shareholders of both organizations.” Bla1se Coleman Prestdent and Chtef Executive Offtcer